Indication
Hypercholesterolemia
111 clinical trials
122 products
2 drugs
Product
RosuvastatinProduct
MK-0616Clinical trial
A Phase III, 6-Month Self-selection and Actual Use Study for Rx-to-OTC Switch of Rosuvastatin 5 mg Once-daily in Combination With a Web AppStatus: Completed, Estimated PCD: 2023-03-01
Clinical trial
An Open-Label, Single-Dose Clinical Study to Evaluate the Pharmacokinetics of MK-0616 in Participants With Varying Degrees of Renal ImpairmentStatus: Completed, Estimated PCD: 2024-01-19
Product
Rosuvastatin CalciumProduct
BR1017-1Product
BR1017-1AProduct
BR1017-1BClinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With Heterozygous Familial HypercholesterolemiaStatus: Active (not recruiting), Estimated PCD: 2025-04-28
Clinical trial
An Open-label, Randomized, Fasting, Single-dose, 2-sequence, 4-period, Crossover Phase 1 Study to Evaluate the Pharmacokinetics and the Safety After Administration of "BR1017-1" and Co-administration of "BR1017-1A" and "BR1017-1B" in Healthy VolunteersStatus: Completed, Estimated PCD: 2024-02-18
Product
PlaceboProduct
Rosuvastatin calciumClinical trial
Multicenter, Prospective, Non-interventional, Observational Study to Confirm the Long-term Efficacy and Safety of Rosuampin Tab. in Patients With Hypertension and HypercholesterolemiaStatus: Active (not recruiting), Estimated PCD: 2024-03-31
Product
RosuampinClinical trial
A Multicenter, Randomized, Double-blind, Placebo-controlled, Parallel-group Trial to Evaluate the Efficacy and Safety of ETC-1002 in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2022-04-18
Product
ETC-1002Clinical trial
A Phase 2 ,Multicentre, Randomised, Double Blind Double Simulation, Placebo and Positive Controlled Study to Evaluate the Efficacy and Safety of HSK31679 in Patients With Hypercholesterolemia With Non-alcoholic Fatty Liver DiseaseStatus: Completed, Estimated PCD: 2024-02-20
Product
HSK31679Product
EzetimibeClinical trial
Open-label, Phase 1b, Single-ascending Dose and Optional re Dosing Study to Evaluate the Safety of VERVE-101 Administered to Patients With Heterozygous Familial Hypercholesterolemia, Atherosclerotic Cardiovascular Disease, and Uncontrolled HypercholesterolemiaStatus: Active (not recruiting), Estimated PCD: 2024-12-01
Clinical trial
Efficacy, Safety, Tolerability and Quality of Life of Ongoing Individually Optimized Lipid-lowering Therapy With or Without Inclisiran (KJX839) - a Randomized, Placebo-controlled, Double-blind Multicenter Phase IV Study in Participants With HypercholesterolemiaStatus: Recruiting, Estimated PCD: 2024-05-27
Product
InclisiranProduct
VERVE-101Clinical trial
A Real-world, Prospective, Multi-center, Open-label, Phase 4 Clinical Study to Evaluate the Safety and Effectiveness of Subcutaneous Injection of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaStatus: Not yet recruiting, Estimated PCD: 2025-08-08
Product
inclisiranClinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of 10 mg Obicetrapib in Participants With a History of HeFH Who Are Not Adequately Controlled by Their Lipid Modifying TherapiesStatus: Active (not recruiting), Estimated PCD: 2024-07-30
Product
ObicetrapibClinical trial
A Randomized, Open-label, Multiple-dose, 6-sequence, 3-treatment, 3-period, Crossover Study to Evaluate the Pharmacokinetic Interaction and Safety Between BR1018-1 and BR1018-2 in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2022-10-17
Clinical trial
A Double-blind, Randomized, Placebo- and Active-Comparator Controlled Study to Evaluate the Efficacy of Inclisiran as Monotherapy in Patients With Primary Hypercholesterolemia Not Receiving Lipid-Lowering Therapy (VictORION-Mono)Status: Recruiting, Estimated PCD: 2024-06-21
Product
MN-001Clinical trial
A Multi-centre Study to Evaluate the Effects of Valsartan and the Combination of Valsartan and Simvastatin on Blood Pressure (Ambulatory and Std Cuff) and on Biochemical Markers of Endothelial Function (hsCRP, MCP-1, Serum F2 Isoprostanes, PAI-1, tPA, PICP, PIIINP, MMP9, MMP1, TIMP 1), Safety and TolerabilityStatus: Completed, Estimated PCD: 2003-04-01
Product
Valsartan + SimvastatinClinical trial
A Multicenter, Randomized, Double-blind, Parallel Group, Placebo-controlled Study to Evaluate the Efficacy and Safety of Inclisiran in Asian Patients With ASCVD or ASCVD High Risk and Elevated Low-density Lipoprotein Cholesterol as an Adjunct to Diet and Maximally Tolerated Statins With or Without Additional Lipid-lowering Therapy (ORION-18)Status: Active (not recruiting), Estimated PCD: 2022-06-09
Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Safety and Efficacy of Evolocumab (AMG 145) in Addition to Optimal Stable Background Statin Therapy in Chinese Subjects With Primary Hypercholesterolemia and Mixed DyslipidemiaStatus: Terminated, Estimated PCD: 2020-04-24
Product
placeboProduct
evolocumabProduct
EZ 10 mg + Ator 10 mgProduct
EZ 10 mg/Ator 20 mgProduct
AtorvastatinProduct
FDC EZ/AtorClinical trial
A Phase 3 Randomized, Active-comparator-controlled Clinical Study to Evaluate the Efficacy and Safety of Ezetimibe/Atorvastatin Combination Tablet (MK-0653C) as Second Line Lipid Lowering Treatment in Chinese ParticipantsStatus: Completed, Estimated PCD: 2021-03-17
Clinical trial
A Multicentric, Randomized, Double-blind, Placebo-controlled Phase III Study to Evaluate the Efficacy and Safety of SHR-1209 in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2022-08-12
Product
SHR-1209Product
Bempedoic Acid/EzetimibeClinical trial
SurveY Followed by a Retrospective Chart Review to Describe the Key Factors Leading to Physician's Decision to Treat Patients at High and Very High Cardiovascular Risk With hyperchOlesterolemia or Mixed Dyslipidemia With NUSTENDI® (Fixed Dose Combination of Bempedoic Acid 180mg and Ezetimibe 10mg) as add-on to Treatment With Maximally Tolerated Statin Therapy in Routine Clinical PracticeStatus: Completed, Estimated PCD: 2022-11-17
Product
EvolocumabClinical trial
A Randomized, Double-Blind, Placebo-Controlled Study of the Safety and Efficacy of Varying Doses and Dose Regimens of Evinacumab in Patients With Persistent Hypercholesterolemia Despite Maximally Tolerated Lipid Modifying TherapyStatus: Completed, Estimated PCD: 2020-05-22
Product
Matching placeboClinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Study to Evaluate Tolerability and Efficacy of AMG 145 on LDL-C in Subject With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2012-05-16
Clinical trial
A Multicenter, Controlled, Open-label Extension (OLE) Study to Assess the Long-term Safety and Efficacy of AMG 145 (Evolocumab)Status: Completed, Estimated PCD: 2018-06-20
Product
EvinacumabClinical trial
A Multicenter, Randomized Study in Subjects With Primary Hypercholesterolemia or Mixed Dyslipidemia to Assess Subjects' Ability to Administer a Full Dose of Evolocumab (AMG 145) in Home-use, Using Either a 3.5 mL Personal Injector or a Prefilled Autoinjector/Pen.Status: , Estimated PCD: 2013-11-15
Clinical trial
An Open-Label Study To Evaluate The Efficacy, Safety, Tolerability and PK of MN-001 (Tipelukast) on HDL Function and Serum Triglyceride Levels in NASH and Non-Alcoholic Fatty Liver Disease (NAFLD) Subjects With HypertriglyceridemiaStatus: Completed, Estimated PCD: 2018-05-30
Product
BR1018-1Product
BR1018-2Clinical trial
A Placebo-Controlled, Double-Blind, Randomized Phase 3 Study to Evaluate the Effect of 10mg Obicetrapib in Participants With HeFH and/or ASCVD Who Are Not Adequately Controlled by Their Lipid Modifying TherapiesStatus: Active (not recruiting), Estimated PCD: 2023-11-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled Study Followed by an Open Label Treatment Period to Evaluate the Efficacy and Safety of Alirocumab in Children and Adolescents With Heterozygous Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2021-01-14
Clinical trial
An Open-Label Study to Evaluate the Pharmacokinetics, Pharmacodynamics, and Safety of Bempedoic Acid in Pediatric Patients (6 to 17 Years of Age) With Heterozygous Familial HypercholesterolemiaStatus: Recruiting, Estimated PCD: 2024-03-24
Product
SimvastatinClinical trial
Non-interventional Study on the Treatment With Bempedoic Acid and/or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia (MILOS)Status: Recruiting, Estimated PCD: 2025-09-01
Product
AlirocumabProduct
PravastatinProduct
LovastatinProduct
FluvastatinProduct
CholestyramineProduct
Nicotinic acidClinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Study to Evaluate the Effect of Obicetrapib 10 mg Daily in Combination With Ezetimibe 10 mg Daily as an Adjunct to High-Intensity Statin Therapy: The ROSE 2 StudyStatus: Completed, Estimated PCD: 2022-08-12
Clinical trial
Randomized, Open-label, Phase 3 Study to Evaluate the Efficacy and Safety of LIB003, Evolocumab and Alirocumab in CVD Patients, or at High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C Reduction (LIBerate-H2H)Status: Completed, Estimated PCD: 2022-09-30
Product
alirocumabClinical trial
A Placebo-Controlled, Randomized, Double-Blind, Parallel Group Study to Evaluate the Efficacy and Safety of ETC-1002 in Patients With Hypercholesterolemia and HypertensionStatus: Completed, Estimated PCD: 2015-05-22
Product
Bempedoic acidClinical trial
A Randomized, Double Blind, Placebo Controlled, Multicenter, Multiple Ascending Dose Study to Evaluate the Safety and Tolerability of HTD1801 in Adults With HypercholesterolemiaStatus: Completed, Estimated PCD: 2018-12-31
Product
HTD1801Clinical trial
Phase III, Multicentre, Randomized, Double-blind, Placebo-controlled Trial Evaluating the Efficacy and Safety of SHR-1209 Monotherapy in Patients With Primary Hypercholesterolemia and Mixed HyperlipemiaStatus: Completed, Estimated PCD: 2022-06-21
Product
lerodalcibepClinical trial
A Prospective, Double-blind, Randomized, Parallel, Multiple-center Study to Compare the Efficacy and Safety of 1PC002 and Atorvastatin in Taiwanese Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2012-09-01
Product
FenofibrateProduct
Omega-3 fatty acidsProduct
1PC002Product
LipitorClinical trial
Study to Evaluate the Long-Term Efficacy and Safety of LIB003 in Patients With Cardiovascular Disease, or at High Risk for Cardiovascular Disease, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C ReductionStatus: Active (not recruiting), Estimated PCD: 2023-11-15
Clinical trial
Randomized Open Label, Phase 3 Study to Compare the Efficacy and Safety of Lerodalcibep (LIB003) to Inclisiran in Patients at Very High or High Risk for CVD, on Stable Lipid-Lowering Therapy Requiring Additional LDL-C ReductionStatus: Active (not recruiting), Estimated PCD: 2024-05-30
Clinical trial
A Randomized, Double-blind, Placebo-controlled, Repeated-dosing, Multiple Ascending Dose Trial to Evaluate the Safety and Tolerability of a Novel PCSK-9 Anti-body, IBI306, in Chinese Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2019-12-25
Clinical trial
A Randomized, Double Blind, Parallel, Multi-center, Phase 3 Clinical Trial to Evaluate the Efficacy and Safety of DW1125 and DW1125A in Patient With Primary Hypercholesterolemia or Mixed DyslipidemiaStatus: Completed, Estimated PCD: 2023-04-13
Product
DW1125Product
DW1125AProduct
DW1125EProduct
DW1125A-1Product
K-924Clinical trial
A Phase III, Multicenter, Randomized, Clinial Trial to Evaluate the Efficacy and Safety of K-924 in Patienta With Hypercholesterolemia.Status: Completed, Estimated PCD: 2020-11-21
Product
K-924 HDProduct
AK102Clinical trial
A Double-blind, Randomized, Placebo-controlled, Multicenter Phase II Study of AK102 in the Treatment of Hypercholesterolemia Patients at Very High or High Risk of Cardiovascular DiseaseStatus: Completed, Estimated PCD: 2021-02-25
Clinical trial
A Long-term Study to Evaluate the Efficacy and Safety of AK102 in Combination With Lipid-lowering Therapy in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2023-02-17
Product
Statins and EzetimibeProduct
Ezetimibe/AtorvastatinProduct
PlacebosProduct
Statins + EzetimibeProduct
IBI306Clinical trial
A Phase 2b, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With HypercholesterolemiaStatus: Completed, Estimated PCD: 2022-11-28
Clinical trial
Non-Interventional Study On The Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed DyslipidemiaStatus: Withdrawn, Estimated PCD: 2026-04-01
Clinical trial
A Multicenter, Open-label Study to Evaluate 52 Weeks Long Term Efficacy and Safety of K-924 in Patients With Hypercholesterolemia Who Were Treated With Pitavastatin 2 mg or 4 mg.Status: Completed, Estimated PCD: 2021-08-07
Clinical trial
A Placebo-controlled, Double-blind, Randomized Trial to Evaluate the Effect of Different Doses of Inclisiran Given as Subcutaneous Injections in Japanese Participants With High Cardiovascular Risk and Elevated LDL-CStatus: Completed, Estimated PCD: 2022-04-18
Product
K-877Clinical trial
A Phase III Confirmatory Study of K-877 (Pemafibrate) in Patients With Hypercholesterolemia and Statin Intolerance-Multicenter, Placebo Controlled, Randomized, Double Blind, Parallel Group Controlled Trial in Patients With Statin Intolerant Hypercholesterolemia-Status: Recruiting, Estimated PCD: 2024-10-31
Clinical trial
A Phase 1, First-in-Human, Dose Escalation Study to Evaluate the Safety, Tolerability, Immunogenicity, and Pharmacodynamics of VXX-401 in Healthy AdultsStatus: Active (not recruiting), Estimated PCD: 2024-06-27
Product
VXX-401Clinical trial
A Study Investigating Pharmacokinetic Properties When Dosing Different Formulations of Oral Peptide Therapeutics in Healthy Male ParticipantsStatus: Completed, Estimated PCD: 2023-02-26
Product
SemaglutideProduct
Semaglutide HProduct
NNC0385-0434Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to Stable Statin Therapy in Japanese Subjects.Status: Completed, Estimated PCD: 2023-04-21
Product
D377Clinical trial
A Randomized, Double-blind, Multi-center, Therapeutic Confirmatory, Phase 3 Trial to Evaluate the Efficacy and Safety of CKD-391 and CKD-331 in Patients With Primary HypercholesterolemiaStatus: Recruiting, Estimated PCD: 2023-06-01
Product
CKD-331Product
D086Product
K-924 LDProduct
FimasartanClinical trial
A Randomized, Double-blind, Multi-center, Phase III Trial to Evaluate the Efficacy and Safety of BR1017A and BR1017B Combination Therapy in Essential Hypertension Patients With Primary HypercholesterolemiaStatus: Recruiting, Estimated PCD: 2024-06-01
Clinical trial
A Multicenter, Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at High Risk for CHD Not Adequately Controlled on Atorvastatin 40 MgStatus: Completed, Estimated PCD: 2008-02-01
Product
atorvastatinProduct
ezetimibeClinical trial
A Phase 3, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of MK-0616 Compared With Ezetimibe or Bempedoic Acid or Ezetimibe and Bempedoic Acid in Adults With HypercholesterolemiaStatus: Not yet recruiting, Estimated PCD: 2025-07-21
Product
Bempedoic AcidClinical trial
Japan Assessment of Pitavastatin and Atorvastatin in Acute Coronary SyndromeStatus: Completed, Estimated PCD: 2007-10-01
Product
PitavastatinDrug
AtorvastatinClinical trial
Effects of Phytoestrogen From Pueraria Mirifica in Improvement of Serum Lipid Parameters in Postmenopausal WomenStatus: Recruiting, Estimated PCD: 2024-08-01
Product
PhytoestrogenClinical trial
Expression of Pro- and Anti-inflammatory Cytokines During Anti-PCSK9 Therapy in Patients With Statin-resistant Familial HypercholesterolemiaStatus: Completed, Estimated PCD: 2020-12-31
Clinical trial
A Phase 3, Double-Blind Efficacy and Safety Study of Ezetimibe (SCH 58235) 10 mg in Addition to Atorvastatin Compared to Placebo in Subjects With Primary Hypercholesterolemia (Protocol P00692)Status: Completed, Estimated PCD: 2001-07-27
Clinical trial
A Multicenter, Randomized, Double-blind, Active-controlled, Phase 3 Study to Evaluate the Efficacy and Safety of Co-administrated BR1018B and BR1018C in Patients With Essential Hypertension and Primary HypercholesterolemiaStatus: Recruiting, Estimated PCD: 2025-04-01
Product
BR1018AProduct
BR1018A-1Product
BR1018BProduct
BR1018B-1Product
BR1018CProduct
BR1018C-1Clinical trial
Long-Term, Safety and Tolerability Study of SCH 58235 or Placebo in Addition to Atorvastatin in Subjects With Primary HypercholesterolemiaStatus: Completed, Estimated PCD: 2002-08-08
Product
AtovastatinClinical trial
Effect of Serum LDL Cholesterol Concentration on Pancreatic Insulin SecretionStatus: Terminated, Estimated PCD: 2024-03-01
Product
PCSK-9 inhibitorProduct
MK0653Clinical trial
A Multicenter, Double-Blind, Randomized, Parallel Group, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2004-03-01
Clinical trial
A Randomized, Double-Blind, Placebo-Controlled, 2-Period, Crossover Study to Evaluate the Effects of Ezetimibe on the Postprandial Lipoprotein Response in Patients With Primary HypercholesterolemiaStatus: Completed, Estimated PCD: 2006-10-24
Product
ComparatorClinical trial
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With Inclisiran in Italy - CHOLINET (CHOLesterol Italian Inclisiran NETwork)Status: Recruiting, Estimated PCD: 2024-02-29
Clinical trial
Examination of the Effect of Ezetimibe on Glucose Metabolism - Randomized, Double-blind, Placebo-controlled Study in Type 2 Diabetes Mellitus Patients With Hypercholesterolemia - Phase 4, Protocol No. 367 (Also Known as SCH 58235, P06541)Status: Completed, Estimated PCD: 2014-01-16
Drug
VarlilumabClinical trial
A Multicenter, Double-Blind, Randomized Study to Establish the Clinical Benefit and Safety of Vytorin (Ezetimibe/Simvastatin Tablet) vs Simvastatin Monotherapy in High-Risk Subjects Presenting With Acute Coronary Syndrome (IMProved Reduction of Outcomes: Vytorin Efficacy International Trial - IMPROVE IT)Status: Completed, Estimated PCD: 2014-09-18
Product
ezetimibe/simvastatinProduct
simvastatinProduct
Placebo for SimvastatinClinical trial
A Multicenter., Rand., Double-Blind, Titration Study to Evaluate & Compare the Efficacy & Safety of Ezetimibe Plus Atorvastatin Vs Atorvastatin in Hypercholesterolemic Pts. at Moderately High Risk for CHD Not Adequately Controlled on Atorvastatin 20 MgStatus: Completed, Estimated PCD: 2008-01-01
Clinical trial
A Multicenter, Randomized, Double-Blind, Titration Study to Evaluate the Efficacy and Safety of Ezetimibe Added On to Rosuvastatin Versus Up Titration of Rosuvastatin in Patients With Hypercholesterolemia at Risk for Coronary Heart DiseaseStatus: Completed, Estimated PCD: 2010-05-01
Product
Rosuvastatin + EzetimibeProduct
Comparator: rosuvastatinClinical trial
A Multicenter, Randomized, Double-Blind, Parallel Arm, 6-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Versus Atorvastatin in Patients With Metabolic Syndrome and Hypercholesterolemia at High Risk for Coronary Heart DiseaseStatus: Completed, Estimated PCD: 2008-07-01
Product
Ezetimibe + SimvastatinClinical trial
A Multicenter, Randomized, Double-Blind, Parallel Arm, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe 10 mg When Added to Atorvastatin 10 mg Versus Titration to Atorvastatin 20 mg and to 40 mg in Elderly Patients With Hypercholesterolemia at High Risk for CHDStatus: Completed, Estimated PCD: 2008-10-01
Product
Ezetimibe + AtorvastatinClinical trial
A Randomized, Double-blind, Active-controlled, Multicenter Phase 3 Trial to Evaluate the Efficacy and Safety of Co-administrated AD-2021 and AD-2022 in Patients With Primary Hypercholesterolemia and Essential HypertensionStatus: Completed, Estimated PCD: 2021-11-22
Product
AD-2021Product
AD-2022Clinical trial
A Randomized, Double-Blind, Active-Controlled Study of Patients With Primary Hypercholesterolemia and High Cardiovascular Risk and Not Adequately Controlled With Atorvastatin: A Comparison of Switching to a Combination Tablet Ezetimibe/Simvastatin Versus Doubling the Baseline Dose of AtorvastatinStatus: Completed, Estimated PCD: 2010-09-01
Clinical trial
A Clinical Study for the Safety and Efficacy of Intravenous Infusion of NGGT006 in Treatment of Refractory HypercholesterolemiaStatus: Not yet recruiting, Estimated PCD: 2025-03-31
Product
NGGT006Clinical trial
Screening for Familial Hypercholesterolemia in Children Using the Blotter Method, or Dried Blood SpotStatus: Completed, Estimated PCD: 2023-02-28
Product
Blood testClinical trial
A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Hypercholesterolemic Patients With Diabetes Mellitus or Metabolic SyndromeStatus: Completed, Estimated PCD: 2007-09-01
Product
Simvastatin + EzetimibeClinical trial
A Double-blind, Randomized, Placebo-controlled, Two-period Crossover Trial to Assess the Effects of 4 g/d Prescription Omega-3 Ethyl Esters on Low-density Lipoprotein Cholesterol in Subjects With Primary HypercholesterolemiaStatus: Completed, Estimated PCD: 2010-07-01
Product
P-OM3Clinical trial
A Multicenter, Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Lipid-Altering Efficacy, Safety, and Tolerability of SCH 58235 When Added to Ongoing Therapy With an HMG-CoA Reductase Inhibitor (Statin) in Patients With Primary Hypercholesterolemia, Known Coronary Heart Disease, or Multiple Cardiovascular Risk FactorsStatus: Completed, Estimated PCD: 2001-07-27
Product
SimivastatinClinical trial
A Placebo-Controlled, Double-Blind, Randomized Phase 2 Study to Evaluate the Effect of Obicetrapib in Combination With Ezetimibe in Participants With Mild DyslipidemiaStatus: Completed, Estimated PCD: 2021-05-07
Clinical trial
Open-label, Long-term Study of Coadministration of Ezetimibe and Atorvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase InhibitorsStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Open-label, Long-term Study of Coadministration of Ezetimibe and Simvastatin in Patients With Primary Hypercholesterolemia Who Have Not Reached LDL-cholesterol Target With HMG-CoA Reductase InhibitorsStatus: Completed, Estimated PCD: 2009-06-01
Clinical trial
Comparison of Effects of Simvastatin Versus Ezetimibe on Intracellular Lipid and Inflammation in Obese SubjectsStatus: Terminated, Estimated PCD: 2021-08-01
Clinical trial
Effects of Dengzhanxixin Capsule on Platelet Function in Individuals at High Risk for Cardiovascular Disease (FUTURE): a Multi-center, Double-blinded, Randomized, Placebo-controlled TrialStatus: Recruiting, Estimated PCD: 2023-12-31
Product
DengzhanxixinClinical trial
A Randomised, Double-blind, Placebo-controlled, Phase III Trial to Study the Effect of Irbesartan on Endothelial Function of the Retinal Vasculature in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2009-12-01
Product
IrbesartanClinical trial
A Phase III, Randomized, Active Comparator-controlled, Clinical Trial to Study the Efficacy and Safety of MK-0653H in Japanese Patients With Hypercholesterolemia.Status: Completed, Estimated PCD: 2017-01-18
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 2 Dose-Finding Study to Evaluate the Effect of Obicetrapib as an Adjunct to High-Intensity Statin TherapyStatus: Completed, Estimated PCD: 2021-05-24
Clinical trial
A Phase 1b Single Ascending Dose Study to Evaluate the Safety of VERVE-201 in Patients With Refractory HyperlipidemiaStatus: Not yet recruiting, Estimated PCD: 2027-03-01
Product
VERVE-201Clinical trial
Multicenter Study on the Evaluation of Adherence, Persistence and Efficacy of Treatment With PCSK9 Inhibitors in ItalyStatus: Recruiting, Estimated PCD: 2024-03-07
Product
RepathaClinical trial
Supplements, Placebo, or Rosuvastatin StudyStatus: Completed, Estimated PCD: 2022-07-19
Clinical trial
A Multicenter, Randomized, Double-Blind, Parallel, 12-Week Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin Combination Tablet Versus Atorvastatin in Elderly Patients With Hypercholesterolemia at High or Moderately High Risk for Coronary Heart DiseaseStatus: Completed, Estimated PCD: 2009-03-01
Product
Ezetimibe/SimvastatinClinical trial
A Randomized, Multicenter, Open-label Trial Comparing the Effectiveness of Inclisiran to Bempedoic Acid on LDL Cholesterol (LDL-C) Lowering in Participants With Atherosclerotic Cardiovascular Disease (VICTORION-CHALLENGE)Status: Not yet recruiting, Estimated PCD: 2025-09-01
Product
BPAClinical trial
PET Imaging of Inflammation and Lipid Lowering StudyStatus: Recruiting, Estimated PCD: 2025-03-01
Product
ColchicineClinical trial
A Multicenter, Randomized, Open Label Study to Evaluate the Lipid Lowering Efficacy and Safety of Vytorin® 10/20 vs. Atorvastatin 10mg in Hypercholesterolemia Patients With Metabolic Syndrome in KoreaStatus: Completed, Estimated PCD: 2008-08-01
Clinical trial
A Phase III, Open-label, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653H in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Rosuvastatin MonotherapyStatus: Completed, Estimated PCD: 2017-12-11
Clinical trial
A Randomized, Double-Blind, Parallel-Group, Placebo-Controlled Efficacy and Safety Study of Ezetimibe Monotherapy in Children (Ages 6 to 10 Years) With Primary Hypercholesterolemia (Heterozygous Familial and Nonfamilial) (Phase 3, Protocol No. P05522)Status: Completed, Estimated PCD: 2012-04-13
Clinical trial
Cardiovascular Risk in Epilepsy: Pilot Feasibility and Efficacy Study of Neurologist-Initiated Treatment of Hypertension and Hyperlipidemia in an Underserved Minority Population in Los AngelesStatus: Not yet recruiting, Estimated PCD: 2027-01-01
Clinical trial
Phase 3 Randomized, Placebo-Controlled Clinical Study to Evaluate the Efficacy and Safety of MK-0616 in Reducing Major Adverse Cardiovascular Events in Participants at High Cardiovascular RiskStatus: Recruiting, Estimated PCD: 2029-11-29
Clinical trial
A Phase III, Randomized, Active Comparator-controlled Clinical Trial to Study the Efficacy and Safety of MK-0653C in Japanese Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2016-05-30
Product
Placebo for EzetimibeClinical trial
A Phase III, Clinical Trial to Assess the Long Term Safety and Tolerability of MK-0653C in Japanese Patients With Hypercholesterolemia Who Have Inadequate LDL-C Control on Ezetimibe or Atorvastatin Calcium MonotherapyStatus: Completed, Estimated PCD: 2016-12-22
Product
EZ 10 mg + Atorva 20 mgProduct
EZ 10 mg/Atorva 10 mg FDCClinical trial
Ezetimibe Phase IV Clinical Study in Patients With HypercholesterolemiaStatus: Completed, Estimated PCD: 2010-05-01
Clinical trial
A MC, DB, Rand, Study to Evaluate Efficacy, Safety and Tolerability of Eze/Simva 10/40 mg, Atorva 40 mg, Rosuva 10 mg in Achieving LDL-C <2 mmol/l in Pts With CVD...on Simva 40 mg With LDL-C ³2 mmol/lStatus: Completed, Estimated PCD: 2008-06-01
Clinical trial
A Placebo-Controlled, Double-Blind, Randomized, Phase 3 Study to Evaluate the Effect of Obicetrapib 10 mg and Ezetimibe 10 mg Fixed Dose Combination Daily on Top of Maximally Tolerated Lipid-Modifying Therapy in Participants With Heterozygous Familial Hypercholesterolemia (HeFH) and/or Atherosclerotic Cardiovascular Disease (ASCVD) or Multiple ASCVD Risk FactorsStatus: Recruiting, Estimated PCD: 2024-10-01
Product
Combination TherapyClinical trial
A Phase III Double-Blind Efficacy and Safety of Ezetimibe (SCH 58235) 10 MG in Addition to Atorvastatin in Subjects With Coronary Heart Disease or Multiple Cardiovascular Risk Factors and With Primary Hypercholesterolemia Not Controlled by a Starting Dose (10 mg) of AtorvastatinStatus: Completed, Estimated PCD: 2001-11-16
Clinical trial
A Randomized, Double-Blind, Active-Controlled, Multicenter Study to Assess the LDL-C Lowering of Switching to a Combo Tab Ezetimibe/Simvastatin (10 mg/20 mg) Compared to Rosuvastatin 10 mg in Patients With Primary High Cholesterol and High Cardiovascular Risk Not Controlled With a Prior Statin TreatmentStatus: Completed, Estimated PCD: 2008-03-01
Clinical trial
A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of MK-0616 in Adults With HypercholesterolemiaStatus: Active (not recruiting), Estimated PCD: 2025-09-15
Clinical trial
Multicenter, Randomized, Double-Blind Study to Evaluate the Efficacy and Safety of Ezetimibe/Simvastatin and Niacin (Extended Release Tablet) Co-Administered in Patients With Type IIa or Type IIb HyperlipidemiaStatus: Completed, Estimated PCD: 2008-02-01
Product
Comparator: NiacinProduct
NiacinClinical trial
A Multicenter, Randomized, Open-label Study to Evaluate the Lipid-Altering Efficacy and Safety of Ezetimibe (+) Simvastatin Versus Atorvastatin in Patients With Primary HypercholesterolemiaStatus: Completed, Estimated PCD: 2007-10-01
Clinical trial
A Multicenter, Randomized, Parallel-Groups, Double-Blind Placebo-Controlled Study Comparing the Efficacy, Safety, and Tolerability of Administration of Ezetimibe/Simvastatin Tablet 10/20 mg Versus Doubling the Dose of Simvastatin 20 mg [Simvastatin 40 mg] in Subjects With Primary Hypercholesterolemia and Coronary Heart DiseaseStatus: Completed, Estimated PCD: 2008-03-01
Clinical trial
Evaluate The Lipid-Lowering Efficacy and Safety of Vytorin in Comparison With Atorvastatin in Hypercholesterolaemic Patients With Coronary Artery DiseaseStatus: Completed, Estimated PCD: 2008-10-01
Clinical trial
Begin With The Right Patients With Dual-Inhibition Action Therapy Through Vytorin for Newly Diagnosed Dyslipidemia PatientsStatus: Completed, Estimated PCD: 2009-07-01
Clinical trial
A Worldwide, Multicenter, Double-Blind, Randomized, Parallel, Placebo-Controlled 12-Week Study to Evaluate the Efficacy and Safety of Extended Release (ER) Niacin/Laropiprant When Added to Ongoing Lipid-Modifying Therapy in Patients With Primary Hypercholesterolemia or Mixed DyslipidemiaStatus: Terminated, Estimated PCD: 2013-02-26
Clinical trial
Open, Randomized, 2-Group, 2-Period, Fasting, Single-Dose, Crossover Study to Evaluate the Bioequivalence of "Crecheck Tablet 2.5 mg (Rosuvastatin Calcium)" of Hanlim Pharm. Co., Ltd. and "Crestor Tablet 5 mg (Rosuvastatin Calcium)" of AstraZeneca Korea Co., Ltd. in Healthy Adult SubjectsStatus: Completed, Estimated PCD: 2023-12-07
Product
Crecheck TabletProduct
Crestor